Correction to: IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.
Authors
Palmieri, CStein, R
Liu, X
Hudson, E
Nicholas, H
Sasano, H
Guestini, F
Holcombe, C
Barrett, S
Kenny, L
Reed, S
Lim, A
Hayward, L
Howell, Sacha J
Charles C
Affiliation
Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, L69 3BX, UKIssue Date
2017-10-25
Metadata
Show full item recordAbstract
In the original publication of the article, a part of acknowledgement section was missed out. The omitted acknowledgement is given below: 'The study was coordinated by the Imperial Clinical Trials Unit-Cancer, Imperial College London and Sponsored by Imperial College London. The Imperial Clinical Trials Unit receives funding from the National Institute for Health (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. This study was supported by Imperial Experimental Cancer Medicine Centre and Cancer Research UK Imperial Centre'.Citation
Correction to: IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients. 2017, Breast Cancer Res TreatJournal
Breast Cancer Research and TreatmentDOI
10.1007/s10549-017-4539-3PubMed ID
29071491Type
ArticleLanguage
enISSN
1573-7217ae974a485f413a2113503eed53cd6c53
10.1007/s10549-017-4539-3
Scopus Count
Collections
Related articles
- IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients.
- Authors: Palmieri C, Stein RC, Liu X, Hudson E, Nicholas H, Sasano H, Guestini F, Holcombe C, Barrett S, Kenny L, Reed S, Lim A, Hayward L, Howell S, Coombes RC, IRIS trial participants
- Issue date: 2017 Sep
- Multivariate profile and acute-phase correlates of cognitive deficits in a COVID-19 hospitalised cohort.
- Authors: Hampshire A, Chatfield DA, MPhil AM, Jolly A, Trender W, Hellyer PJ, Giovane MD, Newcombe VFJ, Outtrim JG, Warne B, Bhatti J, Pointon L, Elmer A, Sithole N, Bradley J, Kingston N, Sawcer SJ, Bullmore ET, Rowe JB, Menon DK, Cambridge NeuroCOVID Group, the NIHR COVID-19 BioResource, and Cambridge NIHR Clinical Research Facility
- Issue date: 2022 May
- Mental health outcomes at the end of the British involvement in the Iraq and Afghanistan conflicts: a cohort study.
- Authors: Stevelink SAM, Jones M, Hull L, Pernet D, MacCrimmon S, Goodwin L, MacManus D, Murphy D, Jones N, Greenberg N, Rona RJ, Fear NT, Wessely S
- Issue date: 2018 Dec
- A phase I dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer.
- Authors: Coombes RC, Cardoso F, Isambert N, Lesimple T, Soulié P, Peraire C, Fohanno V, Kornowski A, Ali T, Schmid P
- Issue date: 2013 Jul